Biotechnologies
ACCELERATING INNOVATIVE

We Acquire, Develop and Finance Undervalued Biomedical Assets

Slider

Our vision is to create a pipeline of innovative biomedical assets in various stages of development in multiple therapeutic areas. Our strategy will minimize risk, share success and accelerate our technologies from incubation to monetization.

Q Biomed Inc. Announces Dr. Rajendra Apte Joins Advisory Board

Distinguished Ophthalmology Specialist Brings Wealth of ExperienceNEW YORK, Sept. 17, 2018 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration development company, is pleased to announce that Rajendra Apte, MD, PhD has joined its...

Q BioMed Inc. Announces FDA Filing for Strontium Chloride Sr89 Injection USP for Relief of Metastatic Cancer Bone Pain

Prior Approval Supplement Filing Under GDUFA Guidelines is Final Step in Approval ProcessNEW YORK, Aug. 20, 2018 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO) (OtherOTC: QBIO), a commercial stage biotechnology acceleration development company, and BioNucleonics,...

Q Biomed Inc. Extends its Exclusive Option Agreement With Washington University in St. Louis for a Novel Companion Biomarker for Monitoring Glaucoma and Initiates a Clinical Study

NEW YORK, July 25, 2018 /PRNewswire/ --Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration development company, is pleased to announce that it is extending its option agreement with Washington University in St. Louis. Under the agreement...

OUR GROWING PIPELINE MITIGATES RISK

Progress
0%

Topical eyedrops for glaucoma

PRECLINICAL

Image is not available
Progress
0%

PRECLINICAL

Chemotherapeutic for liver cancer

Image is not available
Progress
0%

Rare pediatric non-verbal Autism Spectrum Disorder

PRE IND 2/3

Image is not available
Progress
0%

COMMERCIALIZATION

Radio-pharmaceutical for metastatic cancer bone pain

Image is not available
Arrow
Arrow
Slider

OUR PORTFOLIO

METASTATIC CANCER BONE PAIN
CHEMOTHERAPUTIC FOR LIVER CANCER
RARE PEDIATRIC NON-VERBAL DISORDER
TOPICAL EYEDROPS FOR GLAUCOMA & IOP

THE RIGHT
FIRM

Focuses exclusively in the biotechnology and healthcare sectors, targeting a broad spectrum of biomedical products and healthcare solutions. Q’s expertise is in business & product development and the capital formation required for phased advancement of products.

THE RIGHT
SOLUTION

Our team assists companies by utilizing our strategic partners and network of experts to provide public market access for private company assets.  80% of biomedical start ups lack capital and resources to transition from incubation to development and beyond.

THE RIGHT
STRATEGY

Q expects to maximize risk-adjusted returns by focusing on value-driven assets from early stage to near-revenue businesses where the technical, regulatory, and commercial risks have been mitigated or where major valuation inflections are imminent.

Copyright © 2017 Q BioMed, Inc. All Rights Reserved

 

 

CONTACT

366 Madison Ave, 3rd Floor
New York, NY 10022 USA
P: +1 888 357 2435
E: info@qbiomed.com